D.A. Davidson & CO. Boosts Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

D.A. Davidson & CO. boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 1.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 35,475 shares of the medical device company’s stock after purchasing an additional 465 shares during the period. D.A. Davidson & CO.’s holdings in DexCom were worth $4,402,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Sands Capital Management LLC grew its stake in DexCom by 4.3% in the 3rd quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock valued at $1,274,541,000 after buying an additional 557,543 shares in the last quarter. Blair William & Co. IL lifted its holdings in DexCom by 1.7% during the 3rd quarter. Blair William & Co. IL now owns 4,507,153 shares of the medical device company’s stock worth $420,517,000 after purchasing an additional 73,654 shares in the last quarter. Norges Bank bought a new position in DexCom in the 4th quarter worth about $540,178,000. Northern Trust Corp grew its holdings in DexCom by 2.4% during the 3rd quarter. Northern Trust Corp now owns 3,896,515 shares of the medical device company’s stock valued at $363,545,000 after buying an additional 91,249 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of DexCom by 3.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 2,241,701 shares of the medical device company’s stock valued at $278,173,000 after buying an additional 80,740 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on DXCM. Canaccord Genuity Group raised their price objective on shares of DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Citigroup raised their price target on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. UBS Group upped their price target on shares of DexCom from $153.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. StockNews.com raised DexCom from a “hold” rating to a “buy” rating in a research note on Friday, May 17th. Finally, Raymond James upped their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $141.67.

DexCom Stock Performance

NASDAQ:DXCM opened at $130.53 on Thursday. The company has a market capitalization of $51.91 billion, a price-to-earnings ratio of 84.21, a PEG ratio of 3.20 and a beta of 1.23. The business has a 50 day moving average of $133.10 and a 200 day moving average of $123.99. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. DexCom, Inc. has a 1-year low of $74.75 and a 1-year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The firm had revenue of $921.00 million during the quarter, compared to analyst estimates of $911.20 million. On average, sell-side analysts predict that DexCom, Inc. will post 1.78 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 20,321 shares of DexCom stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.61, for a total value of $2,715,088.81. Following the transaction, the executive vice president now owns 80,441 shares in the company, valued at $10,747,722.01. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other DexCom news, EVP Sadie Stern sold 20,321 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total value of $2,715,088.81. Following the completion of the sale, the executive vice president now directly owns 80,441 shares in the company, valued at $10,747,722.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the completion of the transaction, the chief executive officer now owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The disclosure for this sale can be found here. Insiders sold a total of 186,641 shares of company stock worth $25,217,707 over the last three months. Company insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.